These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 24907142)

  • 1. Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
    Allavena C; Dailly E; Reliquet V; Bonnet B; Pineau S; André-Garnier E; Boutoille D; Bouquié R; Raveleau A; Bouchez S; Billaud E; Raffi F
    J Antimicrob Chemother; 2014 Oct; 69(10):2804-8. PubMed ID: 24907142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.
    Gantner P; Reinhart S; Partisani M; Baldeyrou M; Batard ML; Bernard-Henry C; Cheneau C; de Mautort E; Priester M; Fafi-Kremer S; Muret P; Rey D
    HIV Med; 2015 Feb; 16(2):132-6. PubMed ID: 25124291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection.
    Deeks ED
    Drugs; 2014 Nov; 74(17):2079-95. PubMed ID: 25352394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
    Custodio JM; Yin X; Hepner M; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Apr; 54(4):378-85. PubMed ID: 24142299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.
    Rokx C; Verbon A; Rijnders BJ
    HIV Med; 2014 Nov; 15(10):611-4. PubMed ID: 24738660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
    HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients.
    Rokx C; Blonk M; Verbon A; Burger D; Rijnders BJ
    J Acquir Immune Defic Syndr; 2015 Jan; 68(1):36-9. PubMed ID: 25247434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
    HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
    Lambert-Niclot S; Charpentier C; Storto A; Fofana D; Soulie C; Fourati S; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2014 Apr; 69(4):1086-9. PubMed ID: 24302653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
    Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
    Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine.
    Amoroso A; Gilliam BL; Talwani R; Boyce C; Redfield RR; Davis CE
    HIV Clin Trials; 2009; 10(5):320-3. PubMed ID: 19906624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.
    Gianotti N; Poli A; Nozza S; Spagnuolo V; Tambussi G; Bossolasco S; Cinque P; Maillard M; Cernuschi M; Galli L; Lazzarin A; Castagna A
    J Int AIDS Soc; 2015; 18(1):20037. PubMed ID: 26232000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
    Lambert-Niclot S; Charpentier C; Storto A; Fofana DB; Soulié C; Fourati S; Visseaux B; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2013 Jun; 68(6):1237-42. PubMed ID: 23361642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.
    Charpentier C; Lê MP; Joly V; Visseaux B; Lariven S; Phung B; Yéni P; Yazdanpanah Y; Descamps D; Peytavin G; Landman R
    PLoS One; 2015; 10(7):e0134430. PubMed ID: 26226257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
    Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.
    Mora-Peris B; Watson V; Vera JH; Weston R; Waldman AD; Kaye S; Khoo S; Mackie NE; Back D; Winston A
    J Antimicrob Chemother; 2014 Jun; 69(6):1642-7. PubMed ID: 24521854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.